Julia P Gregory
CIK 1226675 · CEO · last filed 2026-05-15
Julia P Gregory is a CEO who has filed 28 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for NRIX, was dated May 15, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $550.3K across reported positions. 12 SEC filings were submitted jointly with Biohaven Pharmaceutical Holding Co Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BHVN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
THE WOODLANDS, TX 77381
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NRIX | Director | 10,750 | $22.35 | $240.3K | $0 | 7 | 2026-05-15 |
| BHVN | Director | 25,665 | $12.08 | $310.0K | -$2.58M | 14 | 2025-05-07 |
| CONTRAFECT Corp (CFRX.W) Delisted | CEO | — | — | — | $0 | 1 | 2016-02-17 |
| CONTRAFECT Corp (CFRX.Z) Delisted | CEO | 50,283 | — | — | $54.3K | 3 | 2015-03-03 |
| LXRX | EVP and CFO | — | $1.68 | — | $0 | 1 | 2008-02-11 |
| LEXICON PHARMACEUTICALS, INC. (LEXG) Delisted | EVP, Corp Dev and CFO | — | — | — | $0 | 1 | 2007-02-15 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-15 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2025-09-17 | NRIX | Exer (M) | +10,750 | $20.0K | EDGAR |
| 2025-05-19 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2025-05-07 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2024-05-20 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2024-05-02 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2023-05-04 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2023-05-04 | NRIX | Grant (A) | — | $0 | EDGAR |
| 2022-10-26 | BHVN | Buy (P) | +9,523 | $100.0K | EDGAR |
| 2022-10-05 | — | Mixed | +16,142 | -$14 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.